Valuation: Cingulate Inc.

Market Cap 82.6M 70.79M 66.22M 60.54M 114M 7.91B 115M 784M 305M 3.97B 310M 303M 13.14B P/E 2026 *
-2.66x
P/E 2027 * -5.46x
Enterprise Value 82.6M 70.79M 66.22M 60.54M 114M 7.91B 115M 784M 305M 3.97B 310M 303M 13.14B EV / Sales 2026 *
-
EV / Sales 2027 * 3.71x
Free-Float
71.71%
Yield 2026 *
-
Yield 2027 * -
1 day+2.34%
1 week+9.02%
Current month+18.58%
1 month+22.41%
3 months+27.07%
6 months-10.41%
Current year+30.88%
1 week 5.01
Extreme 5.01
5.93
1 month 4.24
Extreme 4.245
5.93
Current year 3.16
Extreme 3.16
11.89
1 year 3.16
Extreme 3.16
11.89
3 years 1.8
Extreme 1.8001
187.2
5 years 1.8
Extreme 1.8001
1,236
10 years 1.8
Extreme 1.8001
1,236
Manager TitleAgeSince
Chief Executive Officer 51 2012-04-30
Chief Tech/Sci/R&D Officer 63 2017-12-31
Chief Tech/Sci/R&D Officer 69 2017-12-31
Director TitleAgeSince
Director/Board Member 87 2018-05-31
Director/Board Member 60 2024-02-12
Chairman 51 2012-04-30
Date Insider Type Main position Quantity % Market Cap.
7/16/26 Free

Director

20,000 0.1485%
7/16/26 Free

Founder

80,000 0.5940%
7/16/26 Free

Executive/Senior Manager

100,000 0.7424%
Change 5-day change 1-year change 3-year change Capi.($)
+2.34%+9.02%+35.56%-96.40% 80.71M
-0.74%+3.78%+3.74%+23.10% 51.61B
+1.01%-0.20%+471.68%+564.93% 44.89B
+0.16%+7.88%+36.14%+20.76% 42.77B
-0.66%+2.61%+18.59%+87.04% 42.58B
+0.88%-3.48%+17.20%+57.20% 31.82B
-0.12%+3.84%+33.73%+145.25% 17.33B
-0.53%+1.84% - - 16.63B
+0.58%+4.66%+7.17%+30.87% 14.76B
+1.15%+4.17%+84.49%+50.33% 14.09B
Average +0.41%+5.06%+78.70%+98.12% 27.66B
Weighted average by Cap. +0.10%+4.83%+100.56%+140.97%

Financials

2026 *2027 *
Net sales - 22.27M 19.08M 17.85M 16.32M 30.8M 2.13B 31.13M 211M 82.14M 1.07B 83.61M 81.8M 3.54B
Net income -27.95M -23.95M -22.41M -20.49M -38.66M -2.68B -39.07M -265M -103M -1.34B -105M -103M -4.45B -15.06M -12.9M -12.07M -11.04M -20.83M -1.44B -21.05M -143M -55.54M -724M -56.53M -55.31M -2.4B
Net Debt - -
Logo Cingulate Inc.
Cingulate Inc. is a biopharmaceutical company. The Company offers Precision Timed Release (PTR), which is a drug delivery platform technology to build and advance a pipeline of pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety. Its PTR platform incorporates an erosion barrier layer (EBL) designed to allow for the release of drug substances at specific, pre-defined time intervals. It develops stimulant medications which include CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of ADHD across all three patient segments: children (aged 6 -12), adolescents (aged 13-17), and adults (aged 18+). It also develops CTx-2103 (buspirone), for the treatment of anxiety.
Employees
14
Date Price Change Volume
26-08-24 US$5.680 +2.34% 279,834
26-08-21 US$5.550 +4.13% 234,688
26-08-20 US$5.330 +1.14% 131,603
26-08-19 US$5.270 +1.35% 163,269
26-08-18 US$5.200 -0.19% 103,593
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.680USD
Average target price
21.20USD
Spread / Average Target
+273.24%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CING Stock